Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design

Shah, Umang V.; Joshi, Garima; Sawant, Krutika

doi:10.1016/j.msec.2013.10.038

Cited by 67 publications

(33 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NPs were prepared by dissolving PLGA (25 mg) and drug (15 mg) in 2.5 ml of acetone. The organic phase was added at the rate of 0.5 ml/ min into 5 ml of aqueous phase containing 0.25% w/v Pluronic F68 with continuous stirring on magnetic stirrer at room temperature (Shah et al, 2014). Stirring was continued until the complete evaporation of organic solvent.…”

Section: Formulation Of Lopinavir-loaded Plga Npsmentioning

confidence: 99%

Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

2016

Self Cite

View full text Add to dashboard Cite

Nanoparticles (NPs) can be absorbed via M cells of Peyer's patches after oral delivery leading to passive lymphatic targeting followed by systemic drug delivery. Hence, the study was aimed to formulate PLGA NPs of lopinavir. The NPs were prepared by nanoprecipitation, optimized by 3 3 factorial design and characterized by TEM, DSC, FTIR studies and safety was assessed by MTT assay. In vivo pharmacokinetic studies were performed in rats. The NPs were discrete spherical structures having particle size of 142.1 ± 2.13 nm and entrapment of 93.03 ± 1.27%. There was absence of drug-polymer interaction. Confocal images revealed the penetration and absorption of coumarin-loaded NPs in Caco-2 cells and intestine after oral delivery. There was 3.04 folds permeability and 13.9 folds bioavailability enhancement from NPs. The NPs can be promising delivery system for antiretroviral drug by delivering the drug to lymph (major HIV reservoir site) via direct absorption through intestine before reaching systemic circulation.

show abstract

Section: Formulation Of Lopinavir-loaded Plga Npsmentioning

confidence: 99%

Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The system revealed mucoadhesive properties and provided prolonged drug release up to 8 h. The drug delivery systems based on these nanoparticles spray-dried in the presence of mannitol revealed low density, satisfying flow ability, small aerodynamic diameter and fine powder fraction demonstrating potential as a suitable inhaler powder for the pulmonary delivery of carvedilol [12]. Another group [8] has observed the enhancement of felodipine bioavailability from a formulation based on PLGA nanoparticles. Furthermore, in an ex vivo experiment performed on isolated rat stomach and intestinal segments, the nanovehicles demonstrated sustained release of the antihypertensive drug [8].…”

Section: Polymeric Nanoparticles As Carriers For Therapeutic Agentsmentioning

confidence: 98%

“…Another group [8] has observed the enhancement of felodipine bioavailability from a formulation based on PLGA nanoparticles. Furthermore, in an ex vivo experiment performed on isolated rat stomach and intestinal segments, the nanovehicles demonstrated sustained release of the antihypertensive drug [8].…”

Section: Polymeric Nanoparticles As Carriers For Therapeutic Agentsmentioning

confidence: 99%

“…Moreover, the polymer-based nanocarriers may enhance the bioavailability of poorly water-soluble drugs and provide their sustained release [8,9]. The numerous advantages offered by polymeric nanoparticles as drug delivery systems (DDSs) also include the extension of drug circulation time in the body [10], increased stability of acid-labile drugs [11], uniform drug distribution in the targeted site e.g.…”

mentioning

confidence: 99%

“…Polymer-based nanoparticles can be used as the carrier for numerous biologically active molecules including drugs [18], proteins [7], monoclonal antibodies [13], nucleic acids [19,20], biological extracts [16,21] and others [22]. This review will be especially concerned with the application of polymer-based nanoparticles for the treatment of various disease entities including bacterial [23,24], fungal [25] and parasitic [26] infections, ulcers [11], hypertension [12], angina [8], glaucoma [9], uveitis [27], asthma [22], cancer [15,28], neurodegenerative disease [29] and many others [30,31]. It deserves to be emphasized that several polymers are characterized by satisfying biocompatibility and predictable biodegradability [9,22] while others are non-degradable or undergo slow degradation [22,32].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Recent Developments in Application of Polymeric Nanoparticles as Drug Carriers

Moritz¹,

Geszke-Moritz²

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Nanotechnology is an interdisciplinary field of science offering interesting solutions for many branches of human life. Nanomaterials, defined as structures with at least one dimension below 100 nm, are the focus of increasing research attention as versatile tools for nanomedicine. Among the various nanostructures recently described in the literature, polymeric nanoparticles, characterized by satisfying biocompatibility, have aroused great interest as the carriers for various biologically active substances such as drugs, proteins and nucleic acids. These nanoparticles have already been reported as efficient vehicles for therapeutic agents in many disease entities. They can be delivered to the body via different administration routes. This review addresses recent advances in the usage of polymeric nanoparticles as drug carriers described in the years 2013 and 2014. The advantages of polymeric nanocarriers for medical application are highlighted, including their low toxicity, evaluated in vitro and in vivo. Moreover, the classification of polymeric nanoparticles is presented as well as various protocols of their synthesis (Adv Clin Exp Med 2015, 24, 5, 749-758).

show abstract

Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease

Zhang

Dalan

et al. 2022

Advanced Materials

View full text Add to dashboard Cite

Ischemic heart disease (IHD) is the leading cause of disability and mortality worldwide. Reactive oxygen species (ROS) have been shown to play key roles in the progression of diabetes, hypertension, and hypercholesterolemia, which are independent risk factors that lead to atherosclerosis and the development of IHD. Engineered biomaterial‐based nanomedicines are under extensive investigation and exploration, serving as smart and multifunctional nanocarriers for synergistic therapeutic effect. Capitalizing on cell/molecule‐targeting drug delivery, nanomedicines present enhanced specificity and safety with favorable pharmacokinetics and pharmacodynamics. Herein, the roles of ROS in both IHD and its risk factors are discussed, highlighting cardiovascular medications that have antioxidant properties, and summarizing the advantages, properties, and recent achievements of nanomedicines that have ROS scavenging capacity for the treatment of diabetes, hypertension, hypercholesterolemia, atherosclerosis, ischemia/reperfusion, and myocardial infarction. Finally, the current challenges of nanomedicines for ROS‐scavenging treatment of IHD and possible future directions are discussed from a clinical perspective.

show abstract

Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design

Cited by 67 publications

References 31 publications

Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles

Recent Developments in Application of Polymeric Nanoparticles as Drug Carriers

Reactive Oxygen Species Scavenging Nanomedicine for the Treatment of Ischemic Heart Disease

Contact Info

Product

Resources

About